3D Printed Ileum Targeted Tablet for the Treatment of IgA Nephropathy
Thursday, July 17, 2025
5:24 PM – 5:35 PM EDT
Introduction: IgA nephropathy (IgAN) is a leading cause of chronic kidney disease (CKD) and kidney failure, characterized by chronic, progressive autoimmune kidney damage. Tarpeyo is the first FDA-approved treatment proven to reduce the loss of kidney function in adult patients with IgAN. The drug acts on the terminal ileum, reduces the amount of IgA1 antibodies to achieve the treatment of IgAN. In this study, a 3D printed tablet was designed for the delivery of Budesonide to ileum for modulating B-cell numbers and activity.
Learning Objectives:
At the completion of this activity, participants will know
Precisely deliver budesonide to distal ileum for delayed immediate release in dense target areas.
To reduce the in-vivo variability (Tlag and Tmax) of budesonide compared with Nefecon®
